Boehringer sinks €100M into Respimat production; Impax inks shareholder lawsuit settlement;

@FiercePharma: ICYMI: This week's issue of FierceAnimalHealth. Subscribe here to get it every week. | Follow @FiercePharma

@TracyStaton: ICYMI yesterday: Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack. Story from FierceBiotech | Follow @TracyStaton

@CarlyHFierce: Once-rejected drugs in Gilead's Stribild get FDA nod to go it alone. Story | Follow @CarlyHFierce

> Boehringer Ingelheim is beefing up its Dortmund, Germany, plant to turn out more Respimat inhalers, with a €100 million investment ($126 million) and 100 new jobs. Report

> Generics maker Impax Laboratories ($IPXL) said it will pay $8 million to settle a shareholder lawsuit over allegations that it didn't tell the full truth about FDA inspections at a troubled California plant. Report

> Baxter ($BAX) plans a new R&D facility in Cambridge, MA, for the pharma business it plans to spin off next year under the name Baxalta. Report

> A U.S. judge says securities regulators can go after two Dubai residents for allegedly engaging in insider trading around Amgen's ($AMGN) 2013 deal to buy Onyx Pharmaceuticals. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Activist investor intensifies pressure on Volcano. Article | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Interesting tidbit about off-label use: biliary stents have been used for cardiac indications in the past, panelists say. | Follow @VarunSaxena2

@EmilyWFierce: Closed-loop epidural stimulation system helped paralyzed rats take 1,000 steps and navigate "rodent-sized stairs." More from MIT Technology Review | Follow @EmilyWFierce

> Study: Publicly available information about 510(k) devices' safety and effectiveness lacking. Article

> Israeli devicemaker eyes lucrative sleep disorder market. Story

> Microsoft, Aerocrine partner to send asthma device data to the cloud. Report

Biotech News

@FierceBiotech: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here | Follow @FierceBiotech

@JohnCFierce: Baxter inks a big lease in the heart of Cambridge for biopharma R&D headquarters - (more for hubs, less for Chicago). Article | Follow @JohnCFierce

@DamianFierce: buying antiviral outfit Alios for $1.75B in cash(!). Press release | Follow @DamianFierce

@EmilyMFierce: New class of antibiotics could fight drug-resistant tuberculosis. FierceBiotech Research story | Follow @EmilyMFierce

> Takeda steps up with $1.6B package of milestones in MacroGenics R&D pact. More

> Regeneron's would-be blockbuster completes the allergic circle with Phase II success. Article

> J&J makes a splash in hep C with a $1.75B deal for Alios. News

Biotech Research News

> New class of antibiotics could fight drug-resistant tuberculosis. More

> Protein 'map' points way to combating chemo-resistant cancer. Report

> Scientists replicate ALS dementia in mice. Item

> Hemispherx to test FDA-rejected drug, other candidates against Ebola. Article

> Monkey study reveals clues for HIV eradication. Story

Pharma Manufacturing News

> Report: Indian government to take legal action over drug quality paper. Item

> Apotex tries to 'set the record straight' after Health Canada quarantine request. More

> FDA warns of contaminated Chinese meds after toddler suffers lead poisoning. Article

> Strides and Shasun plan merger to create big, 'de-risking' production network. Story

> Credit Suisse: FDA 483 unlikely to lead to import alert for Sun. Report

And Finally... Working long hours may be boosting the risk of Type 2 diabetes. Report

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.